Discontinuation of benralizumab in Canadian...

Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma

Abstract

Within 1 year, 15% of Canadian patients with severe asthma discontinue benralizumab. The reasons for discontinuation are not yet characterised. https://bit.ly/3kaRDlp.

Authors

Noorduyn SG; Johnston K; Osenenko K; Sriskandarajah N; Gendron A; Mbuagbaw L

Journal

ERJ Open Research, Vol. 7, No. 4, pp. 00465–02021

Publisher

European Respiratory Society (ERS)

Publication Date

October 1, 2021

DOI

10.1183/23120541.00465-2021

ISSN

2312-0541

Associated Experts

Lawrence Mbuagbaw

Professor, Faculty of Health Sciences

Visit profile

Labels